Codexis Shares Up 31% on Roche Licensing Agreement
Provided by
Dow Jones
By Josh Beckerman
Codexis shares rose 31% as the enzyme engineering company entered an exclusive licensing agreement with Roche Holding for its newly engineered double-stranded DNA ligase and its EvoT4 DNA ligase.
The stock was recently at $4.18 on Tuesday and is up about 37% this year.
Codexis said the newly engineered ligase improves the ligation efficiency of DNA fragments and adapters during next-generation sequencing.
The deal, which supersedes a prior exclusive license for EvoT4, includes upfront and technical milestone payments.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
February 27, 2024 13:16 ET (18:16 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
SiriusXM Earnings: Decent Results With Plan for Technology and Content Investment to Drive Growth
-
Coca-Cola Earnings: Solid Volume On Innovation and Digital Engagement
-
Is Berkshire Hathaway a Buy Before the Annual Meeting?
-
Investment Opportunities in the Drug Distribution Industry
-
Why the End of Quantitative Tightening Matters
-
Eli Lilly Earnings: Strong Weight-Loss Drug Sales Expand Margins
-
After Earnings, Is Meta Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Boeing Stock a Buy, a Sell, or Fairly Valued?